ABBVIE (ABBV) DIvidends Date & History

Key Takeaways

• AbbVie pays a quarterly dividend of $1.73 per share, for an annualized total of $6.92.
• The current dividend yield stands at approximately 2.7%.
• The company has raised its dividend annually for 14 consecutive years since its 2013 spin-off.
• Free cash flow provides solid coverage for the dividend despite a high GAAP payout ratio.
• AbbVie qualifies as a Dividend Aristocrat with a history of consistent increases.
• The dividend profile appeals to investors seeking moderate yield combined with growth potential.

Dividend Overview

AbbVie maintains a quarterly dividend payment schedule with the most recent declaration setting the payout at $1.73 per share. This results in an annualized dividend of $6.92 and a forward yield near 2.7%. The company is viewed as a dividend growth stock rather than a high-yield name, emphasizing steady increases supported by its diversified pharmaceutical portfolio. Payments occur four times per year, with ex-dividend dates typically falling in January, April, July, and October.

Dividend History and Growth

Since its separation from Abbott Laboratories in 2013, AbbVie has increased its dividend every year for 14 consecutive years. Annual payouts have risen from $3.59 in 2018 to the current $6.92 annualized rate. Recent quarterly hikes include the move from $1.64 to $1.73 in early 2026. The firm belongs to the S&P 500 Dividend Aristocrats Index, reflecting a long-term commitment to shareholder returns through consistent dividend growth.

Dividend Sustainability and Payout Ratio

AbbVie’s GAAP payout ratio appears elevated at around 190% to 275% in recent periods. However, the adjusted payout ratio based on earnings and free cash flow coverage remains more moderate, typically in the 45% to 65% range. Strong free cash flow generation supports ongoing dividend payments and increases. The company maintains a solid balance sheet with manageable debt levels relative to its cash-generating ability, contributing to dividend sustainability over the long term.

Dividend Compared to Industry Peers

Within the pharmaceutical sector, AbbVie’s yield of approximately 2.7% exceeds that of Johnson & Johnson while remaining below higher-yielding names such as Pfizer. Peers like Merck and Amgen generally offer comparable or lower yields. AbbVie stands out for its combination of moderate yield and proven dividend growth track record, positioning it favorably against competitors focused more on high current yields or minimal payouts.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore opportunities with the AI Screener today.

Is This Stock Attractive for Dividend Investors?

AbbVie may suit income-oriented investors seeking a moderate yield with a history of annual increases. Dividend growth investors could find the 14-year streak and free cash flow support appealing for long-term compounding. Conservative investors may appreciate the company’s established position in key therapeutic areas and Aristocrat status, which signals capital allocation discipline. The stock offers a balanced profile for those prioritizing sustainability over the highest available yields in the sector. All investors should evaluate their own objectives and risk tolerance before making decisions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.